To evaluate the ability of a TKI plus PIM inhibitor treatment to block tumor growth of ETP-ALL in vivo, H-SB2 cells stably expressing luciferase (H-SB2-luc; 200,000 cells/100 μL PBS) were injected intravenously into sub-lethally irradiated (2.5 Gy) NOD/SCID IL-2Rγ−/− (NSG) mice. Here, IL2RG is linked to acute lymphoblastic leukemia.